Skip to main content
CJC-1295 Online

An online reading room for the CJC-1295 research record — the GHRH analog, its DAC variant, and the pharmacokinetics that separate them.

04 / questions about findings and risks

CJC-1295 Answers Start With Findings and Their Limits

Blood tests found hormone rises, without proving better health. These twenty-five answers explain CJC-1295 forms, brief effects, and what remains unknown. Your health questions extend beyond those blood-test findings.

Hormone Findings Answer Less Than You Might Expect

Blood tests after CJC-1295 measured hormone rises, without proving lasting health gains. Each answer below explains the finding and what the study leaves open.

CJC-1295 Is Made to Copy the Body's Starting Hormone

The lab-made 30-amino-acid chain consists of protein building blocks. The chain imitates the body's hormone that begins growth hormone release. Four changes slow the chain's breakdown. The linked form attaches to one of the blood's proteins.

Half the linked form leaves blood in about 8 days [1][3].

CJC-1295 Starts a Rise in Hormones From the Gland and Liver

Growth hormone rises when the substance reaches the gland beneath your brain. That rise prompts the liver to make its own growth-related hormone. Repeated linked-form shots kept this liver hormone high for days or weeks [3][4].

CJC-1295 Keeps Prompting Release While the Gland Still Sends Bursts

With the linked form, hormone release continues between study shots. The gland sends growth hormone into blood in separate bursts [3][4]. The body's natural starting hormone disappears from blood within minutes. Half the linked form remains for roughly 8 days.

Four changes help the protein building blocks resist breakdown [2].

CJC-1295 With DAC Joins Blood Protein; the Unlinked Form Does Not

DAC names the extra link for attaching the substance to blood protein. Joining keeps CJC-1295 in blood for days before half leaves. The unlinked form, modified GRF, loses half in roughly 30 minutes. The unlinked form produces a briefer rise in growth hormone [3][10].

CJC-1295 Takes Longer to Leave Blood When the Link Is Present

Studies in healthy adults found the linked form, CJC-1295-DAC, stayed for days [3]. Half the unlinked form left blood in about 30 minutes [10]. This measure describes time left in blood, rather than time until benefit. Joining a blood protein explains why the linked form remains longer.

CJC-1295 Study Shot Timing Does Not Set Timing for Your Care

Research accounts describe the linked form given once or twice weekly [3][9]. Accounts about the unlinked form describe daily skin shots or bedtime shots [10]. Reported timing reflected each form's time left in blood.

The accounts don't establish safe timing for your treatment.

CJC-1295 Brief Effects Include Hot, Red Skin and Tingling

Flushing means hot, red skin, usually on the face. Reports also describe mild headache and red shot sites. Fluid buildup, brief numbness, tingling, and dizziness were reported too [3][15]. Two stage 1 early safety tests reported no serious unwanted reactions at tested amounts [3][4].

CJC-1295 Lasting Hormone Rises Raise Concerns Beyond Brief Reactions

When growth hormones stay high, researchers worry about lasting effects. Insulin may have more trouble keeping blood sugar under control. Fluid can build up, and cells may multiply too much [15]. These concerns don't prove the substance causes cancer. A fatal heart attack stopped the 2006 stage 2 trial. The company considered a direct link unlikely, but still ended development [5][9].

CJC-1295 With Ipamorelin Has Reported Effects a Trial Has Not Checked

People trying the pair outside controlled studies report effects like CJC-1295 alone. They also describe brief hunger and mild stomach trouble [12]. These are personal accounts; a controlled trial hasn't checked the reports.

Neither stage 2 benefit testing nor larger stage 3 studies have settled lasting safety of the pair [12].

CJC-1295 Early Safety Results Do Not Answer the Long-Term Question

Drug regulators haven't approved the substance for treating people [16]. Two stage 1 early safety tests studied healthy adults. Brief safety findings were acceptable at the amounts tested [3][4]. These small studies can't settle lasting safety.

A participant's death during company trials stopped development [5].

CJC-1295 Research Has Not Established an Increase in Testosterone

The studies haven't shown that CJC-1295 directly raises testosterone [3]. Testosterone belongs to the sex hormones. Growth hormone release and the liver are affected by the substance. Glands controlling sex hormones aren't directly affected. Reports elsewhere describe possible changes following growth hormone activity.

Those are possible indirect effects, without an established testosterone change.

CJC-1295 Can Affect Hormones Involved in Blood Sugar and Fluid

Repeated linked-form shots raise growth hormone and the liver hormone [3]. Wider research on excess growth hormone describes blood sugar becoming harder for insulin to control. The body may hold extra salt and water, causing swelling [15]. These possible effects aren't proven risks for each patient. Direct effects on sex-hormone glands haven't been shown [3].

CJC-1295 With Ipamorelin Can Increase Release Through Two Starting Steps

Researchers pair CJC-1295 with ipamorelin because each starts growth hormone release differently. The first substance raises release between bursts; ipamorelin adds a brief burst. Animal tests found no rise in cortisol or prolactin from ipamorelin [12]. Cortisol is a stress hormone; prolactin helps with milk production. The different starting steps let the effects add together.

CJC-1295 With Ipamorelin Has Reports of Changes, Without Proof of Benefit

Blood tests found the liver hormone rose within days after CJC-1295-DAC [3]. People trying the substances outside controlled studies report changes they noticed. A trial with placebo, a treatment without the substances, hasn't checked those accounts.

Neither stage 2 benefit tests nor larger stage 3 trials measured how large those changes were.

CJC-1295 Hormone Rises Do Not Show When Muscle or Fat Will Change

The linked form raises blood growth hormone and the liver hormone within days [3]. People trying CJC-1295 outside controlled studies report muscle or fat changes. A trial hasn't checked these personal accounts.

No completed stage 2 benefit test or larger stage 3 study compared those changes with placebo [9]. Placebo is a comparison treatment without the substance.

CJC-1295 With Ipamorelin: The 5mg Label Leaves Each Amount Unclear

The bottle amount in the heading doesn't state each substance's share. A milligram measures a small weight. Product papers describe clean mixing, gentle swirling, and storage at 2-8 degrees celsius [14]. Celsius measures temperature; that range is refrigerator cold, above freezing. Water amounts depend on how much substance the bottle holds. Neither substance has a medically reviewed human mixing standard.

CJC-1295 DAC Names the Form With the Added Link

The extra link joins a blood protein, which slows breakdown. Half the linked substance leaves blood in about 8 days [1]. The joined substance and protein weigh 67 kilodaltons. Kilodaltons measure weights too small for an ordinary scale.

The kidneys can't filter out the substance joined to that protein.

Four Changes Slow Breakdown Without the Link That Holds Blood Protein

The unlinked CJC-1295 form has four changes in its protein building blocks. The changes slow breakdown, without attaching the substance to blood protein. Half the unlinked form leaves blood in roughly 30 minutes.

Growth hormone rises more briefly than with the linked CJC-1295-DAC form [10].

CJC-1295 Study Amounts Cannot Set a Personal Dose

The research doesn't establish a human dose for your care. Stage 1 early safety tests studied increasing amounts beneath the skin. Some groups had weekly shots or shots every second week. Research accounts describe 100 micrograms of the unlinked form beneath the skin before bed [3][9][10]. A microgram measures a very small weight of the substance. These descriptions aren't instructions for your treatment.

CJC-1295 Copies a Different Starting Hormone From Ipamorelin

CJC-1295 copies the body's starting hormone for growth hormone release. Ipamorelin acts where the hunger hormone, called ghrelin, acts [12]. The substances reach hormone-making cells at different points. Researchers study the pair because the separate effects can add together.

Each substance starts release differently rather than repeating the other's step.

CJC-1295 Pharmacy Requests Were Withdrawn Without Granting FDA Approval

FDA hasn't approved the substance for treating any illness [16]. A death ended company development during a 2006 stage 2 trial [5]. FDA's page current as of April 22, 2026 lists withdrawn requests. The requests asked FDA to consider pharmacies mixing CJC-1295 and ipamorelin acetate. Acetate names the salt form of ipamorelin. The safety warnings remain. Ipamorelin acetate remains in Category 2, the group flagged for safety concerns. That listing concerns businesses making large batches for clinics or pharmacies. The category doesn't give those businesses permission to prepare the substance. Other rules cover pharmacies mixing medicine for one patient's prescription. Withdrawal doesn't explain their right to prepare either substance [16]. Sports rules ban the substance both during contests and between contests [7].

A Famous Name Does Not Prove That a Treatment Helps

Stories about famous people trying peptides aren't findings from human trials. A peptide consists of protein building blocks making a short chain. Personal accounts can't establish that CJC-1295 improves health. Published studies here describe blood tests, time in blood, and approval limits.

A famous person's account doesn't answer your questions about lasting benefits.

Tesamorelin Reduced Deep Belly Fat in HIV Patients

Wider growth hormone research links lasting rises with less deep belly fat [15][17]. Tesamorelin is a different substance that prompts growth hormone release. Tesamorelin alone has approval among substances copying that starting hormone. In the tesamorelin study, patients had abnormal fat changes linked with HIV. The HIV virus can weaken your immune system. Over 26 weeks, fat deep in their bellies fell about 15% [17]. CJC-1295 has no comparable findings from trials against placebo.

Results from a different substance can't establish what would help you.

Combining Growth-Hormone Substances May Increase the Risk of Unwanted Cell Growth

Medical reviews warn about combinations that further increase growth hormone release. CJC-1295 with added insulin or muscle-building drugs raises similar concerns. Growth hormone and the liver hormone can rise further together. Blood sugar may become harder for insulin to control. Cells may multiply more than the body needs [15].

The reviews favor caution when several substances raise these hormones together.

CJC-1295 Swallowed or Given Through the Nose Lacks Human Trial Support

All published human trials gave the substance by shots beneath the skin [13]. Chemicals in the stomach break down the chain when swallowed. The intact chain can't then get into blood. Researchers explored nose delivery for related substances.

Published human trials haven't established nose delivery for CJC-1295 [13].